AFP and hepatocellular carcinoma: In addition, compared to AFP, EV-DLEU2 showed a higher negative rate in the CH and liver cirrhosis groups and a higher positive rate in the HCC group, suggesting that EV-DLEU2 has a good ability to distinguish between HCC and non-HCC patients.